While Wnt inhibitors, such as those disrupting β-catenin/TCF interactions, blocking coactivators like CBP, or inhibiting kinases like TNIK, suppress tumor growth and enhance immune infiltration by disrupting key signaling pathways, RBP inhibitors interfere with post-transcriptional regulation, affecting RNA stability and the translation of Wnt components and related oncogenes. The gene discussed is HNF4A; the disease is neoplasm.